A Kansas City, Missouri-based clinical investigational site is working overtime during the COVID-19 pandemic, which is quite the opposite for many research sites that saw their work with sponsors crawl to a halt during the slow downs. Alliance for Multispecialty Research (AMR), a near-nationwide operation, is actually working on two COVID-19 vaccine trials and Dr. John Ervin, founder of the Center for Pharmaceutical Research (acquired by AMR) serves as principal investigator for both experimental vaccines at this site. He might have an important vantage on the potential timelines.
In a recent local KMBC 9ABC news story, news anchor Emily Holwick caught up with the clinical investigator who reported that AMR in Kansas City was the first site selected by INO-4800 vaccine sponsor Inovio Pharmaceuticals. Dr. Ervin told Channel 9’s Holwick that AMR has conducted over 100 vaccine clinical trials and, in fact, “over 800 trials since 1986,” which is a lot of studies. He continued that they even served as a site for Inovio’s Ebola vaccine study.
How are the COVID-19 Vaccines Coming Along?
Dr. Ervin reports that they are serving as a site for both Inovio and Moderna (mRNA-1273). G...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).